Abstract: The present disclosure provides a negative electrode material that can improve the cycle characteristics of a battery. The negative electrode material according to the present disclosure contains a reduced form of a solid electrolyte material. The solid electrolyte material is denoted by Formula (1): Li?M?X?. Herein, in Formula (1), each of ?, ?, and ? is a value greater than 0, M represents at least one element selected from the group consisting of metal dements except Li and semimetals, and X represents at least one dement selected from the group consisting of F, Cl, Br, and I.

Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.

Abstract: An annular step portion provided to a periphery of a wafer housing portion is provided to an area with which an area of 1 to 6 mm from a boundary line with a chamfered surface of a wafer rear surface toward a wafer center comes in contact. As a result, it is possible to produce an epitaxial wafer having no scratch in a boundary area between the rear surface and the chamfered surface, and to eliminate particles generated due to a scratch in a device process.

Abstract: An annular step portion provided to a periphery of a wafer housing portion is provided to an area with which an area of 1 to 6 mm from a boundary line with a chamfered surface of a wafer rear surface toward a wafer center comes in contact. As a result, it is possible to produce an epitaxial wafer having no scratch in a boundary area between the rear surface and the chamfered surface, and to eliminate particles generated due to a scratch in a device process.

Abstract: The present invention is directed to provide a method for holding a silicon wafer, which can reduce contact scratches in contact with support members when holding a back surface of the silicon wafer, as well as prevent the wafer from bending when holding the back surface of the silicon wafer. The back surface of a silicon wafer of 300 millimeters or more in diameter and 700 micrometers to 1000 micrometers in thickness is held in contact with a support member or a suction member, specifically held within a region where a radius of the silicon wafer×0.50 to 0.80 from a center thereof. The silicon wafer is held in a state where the maximum amount of displacement within a wafer plane is 300 micrometers or less. The silicon wafer back surface is held in contact within the holding region in all the processes of holding the back surface of the silicon wafer in contact with the support member or the suction member.

Abstract: An epitaxial silicon wafer in which on growing an epitaxial film only on the front side of a large-sized wafer which is 450 mm or more in diameter, the wafer can be decreased in warpage to obtain a high intrinsic gettering performance and a method for producing the epitaxial silicon wafer. Intrinsic gettering functions have been imparted to a high resistant large-sized silicon wafer which is 450 mm or more in diameter and 0.1 ?·cm or more in specific resistance by introducing nitrogen, carbon or both of them to a melt on pulling up an ingot. Thereby, after the growth of an epitaxial film, a silicon wafer is less likely to warp greatly. As a result, it is possible to decrease the warpage of an epitaxial silicon wafer and also to obtain a high intrinsic gettering performance.

Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.

Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.

Abstract: The present invention relates to a method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases, a method of discriminating leukemia from pre-leukemia or aleukemic malignant blood diseases, a method of discriminating aplastic anemia from myelodysplastic syndrome, a method of diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells, and a method of diagnosing the graft versus host disease, each of said methods comprising quantifying stem cell growth factor (SCGF). The present invention also makes it possible to provide an agent for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases and an agent for diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells or an agent for diagnosing graft versus host disease (GVHD), each containing as an active ingredient an antibody reacting with stem cell growth factor (SCGF).

Abstract: In a susceptor (10) having a wafer pocket (101) for receiving a wafer W at the time of vapor-phase growth, the wafer pocket has at least a first pocket portion (102) for loading an outer circumferential portion of the wafer and a second pocket portion (103) formed to be lower than the first pocket and having a smaller diameter than that of the first pocket portion, and a fluid passage (105) having one end (105a) opening on a vertical wall (103a) of said second pocket portion and the other end (105b) opening on a back surface (104) or a side surface (106) of the susceptor is formed.

Abstract: The present invention provides a screening method of a substance which inhibits binding of a condensed purine derivative to a pancreatic ? cell or a treated product of the cell, a substance which inhibits binding of a condensed purine derivative to a protein capable of the condensed purine derivative, and a substance which inhibits the expression or enzymatic activity of a protein capable of a condensed purine derivative, which comprises using the condensed purine derivative and a pancreatic ? cell or a treated product of the cell or a protein capable of binding to the condensed purine derivative.

Abstract: The present invention relates to a method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases, a method of discriminating leukemia from pre-leukemia or aleukemic malignant blood diseases, a method of discriminating aplastic anemia from myelodysplastic syndrome, a method of diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells, and a method of diagnosing the graft versus host disease, each of said methods comprising quantifying stem cell growth factor (SCGF). The present invention also makes it possible to provide an agent for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases and an agent for diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells or an agent for diagnosing graft versus host disease (GVHD), each containing as an active ingredient an antibody reacting with stem cell growth factor (SCGF).

Abstract: Provided is an isolated phytase derived from a microorganism. The microorganism is preferably from the genus Monascus. The phytase has a Michaelis constant of 10 to 110 &mgr;M when phytic acid is used as a substrate. A process for producing the phytase is also provided as is an animal feed comprising the phytase. The phytase is preferably isolated from Monascus anka IFO 30873. The phytase has a Km of 107 &mgr;m when phytic acid is used as a substrate, the optimum pH is 2.5, the optimum temperature is 45° C., the molecular weight of the phytase is 140 kDa when measured by gel filtration, and the isolectric point is 5.2 using chromatofocusing.

Abstract: The present invention provides phytases having low Km values for phytic acid, a process for producing the phytases by using a microorganism having the ability to produce and accumulate the phytases and feed containing the phytases.

Abstract: The present invention relates to a polypeptide having 25-hydroxyvitamin D3-1&agr;-hydroxylase activity, being useful for the prevention, diagnosis and therapeutic treatment of adult diseases such as osteoporosis induced by the decrease of active type vitamin D3 and catalyzing the final stage of vitamin D3 activation; and the gene encoding the polypeptide.

Abstract: The phytase is preferably isolated from Monascus anka IFO 30873. The phytase has a Km of 20 &mgr;m when phytic acid is used as a substrate, the optimum pH is 6.0, the optimum temperature is 50° C., the molecular weight of the phytase is 120 kDa when measured by gel filtration, and the isolectric point is 4.8 using chromatofocusing.

Abstract: The present invention relates to a polypeptide having 25-hydroxyvitamin D3-1&agr;-hydroxylase activity, being useful for the prevention, diagnosis and therapeutic treatment of adult diseases such as osteoporosis induced by the decrease of active type vitamin D3 and catalyzing the final stage of vitamin D3 activation; and the gene encoding the polypeptide. In accordance with the present invention, the following can be provided; a polypeptide having 25-hydroxyvitamin D3-1&agr;-hydroxylase activity, DNA encoding the polypeptide, a recombinant DNA prepared by inserting the DNA in a vector, a transformant carrying the recombinant DNA, a method for preparing 25-hydroxyvitamin D3-1&agr;-hydroxylase by using the transformant, a method for preparing 1&agr;, 25-dihydroxyvitamin D3 comprising using the polypeptide having 25-hydroxyvitamin D3-1&agr;-hydroxylase activity, and an antibody recognizing the polypeptide.

Abstract: Provided is an isolated phytase derived from a microorganism. The microorganism is preferably from the genus Monascus. The phytase has a Michaelis constant of 10 to 110 &mgr;M when phytic acid is used as a substrate. A process for producing the phytase also is provided, as is an animal feed comprising the phytase.

Abstract: A method and apparatus for processing printed paper in a cut-sheet feed rotary press comprising receiving printed sheets from a printing press on a receiving device at a paper discharge, one sheet at a time, and stacking such received sheets, one on the other, withdrawing and transferring the stacked sheets to a further processing station, the apparatus comprising a printing press having a paper discharge, a paper-receiving device at the paper discharge for receiving the discharged paper, and a conveyer for conveying the paper-receiving device with the discharged paper thereon, from the paper discharge to a further processing station for the discharge of paper therefrom and for returning the paper-receiving device to the paper discharge after the printed paper thereon have been discharged therefrom at the further processing station.

Abstract: The present invention provides a polymer comprising a polysaccharide having excellent water absorption properties, moisture absorption properties, moisture retention properties and thickening properties. Said polysaccharide has the following properties: (A) the principal constituents of the sugar composition are rhamnose, fucose, glucose and glucuronic acid which are present in a molar ratio of (1-4):2:(1-8):(1-4); (B) elemental analysis (wt %):C: 36 .+-.3H: 7 .+-.1O: 56 .+-.4,containing 9-13% of crystalline water(C) solubility:slightly soluble in water; soluble in alkalies; insoluble in methanol, ethanol and acetone;(D) UV absorption spectrum:no absorption detected at 280 nm characteristic of proteins (peptides) or at 260 nm characteristic of nucleic acids; and(E) IR absorption spectrum:an absorption pattern characteristic of polysaccharides is observed near 800-1200.sup.-iSaid polysaccharide is produced by a fermentation method using a natural medium or a synthetic medium of Alcaligenes microorganism.